Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: A meta-analysis

被引:24
作者
Zhang, Chun-Yu [1 ]
Sun, Ai-Jun [1 ,2 ]
Zhang, Shu-Ning [1 ]
Wu, Chao-Neng [1 ]
Fu, Ming-Qiang [1 ]
Xia, Guang [1 ]
Wang, Ke-Qiang [1 ]
Zou, Yun-Zeng [1 ,2 ]
Ge, Jun-Bo [1 ,2 ]
机构
[1] Fudan Univ, Zhongshan Hosp, Shanghai Inst Cardiovasc Dis, Shanghai 200032, Peoples R China
[2] Fudan Univ, Inst Biomed Sci, Shanghai 200032, Peoples R China
基金
中国国家自然科学基金;
关键词
Cardiovascular events; intensive glucose control; meta-analysis; randomized controlled trials; type; 2; diabetes; PIOGLITAZONE CLINICAL-TRIAL; MULTIFACTORIAL INTERVENTION; PRIMARY PREVENTION; DISEASE; MELLITUS; COMPLICATIONS; RISK; METFORMIN; OUTCOMES; PEOPLE;
D O I
10.3109/07853891003796752
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. The effects of intensive glucose control over conventional glucose control on cardiovascular outcomes of patients with type 2 diabetes remain uncertain. Methods. We searched MEDLINE, EMBASE, and the Cochrane database to identify randomized controlled trials that compared the effects of intensive glucose control and conventional glucose control, on cardiovascular events in patients with type 2 diabetes. Results. Seven trials involving 34,144 participants with type 2 diabetes were included. Intensive glucose control significantly reduced major cardiovascular events by 10% (relative risk (RR) 0.90, 95% CI 0.85-0.96; P - 0.0006), and non-fatal myocardial infarction by 16% (0.84, 95% CI 0.76-0.93; P = 0.0006) at the expense of increased incidence of severe hypoglycemia (2.30, 95% CI 1.74-3.03; P < 0.00001), while all-cause mortality, cardiovascular death, non-fatal stroke, and heart failure were similar between the two groups. Subgroup analyses showed that patients with longer follow-up duration, shorter diabetic duration, less glycosylated hemoglobin (HbA1c) reduction, higher HbA1c concentration at follow-up, and lower base-line HbA1c benefited more from intensive glucose control. Conclusion. An intensive glucose control strategy can effectively reduce the risk of major cardiovascular events but at the expense of a significantly increased risk of severe hypoglycemia in patients with type 2 diabetes.
引用
收藏
页码:305 / 315
页数:11
相关论文
共 33 条
  • [1] Cardiovascular events and correlates in the Veterans Affairs diabetes feasibility trial - Veterans Affairs Cooperative Study on gylcemic control and complications in type II diabetes
    Abraira, C
    Colwell, J
    Nuttall, F
    Sawin, CT
    Henderson, W
    Comstock, JP
    Emanuele, NV
    Levin, SR
    Pacold, I
    Lee, HS
    Silbert, CK
    Cxypoliski, R
    Vasquez, M
    Kernan, D
    Niewoehner, C
    Backes, M
    Bradley, M
    Bradley, M
    Crow, R
    Rubino, F
    Bushnell, D
    Pfeifer, M
    Service, FJ
    Howard, B
    Chew, E
    Hoogwerf, B
    Seigel, D
    Clark, CM
    Olefsky, JM
    Porte, D
    Sussman, KE
    Johnson, N
    Christine, B
    Tir, K
    Sather, M
    Day, P
    Morgan, N
    Deykin, D
    Gold, J
    Huang, P
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (02) : 181 - 188
  • [2] Buse JB, 2007, DIABETES CARE, V30, P162, DOI [10.2337/dc07-9917, 10.1161/CIRCULATIONAHA.106.179294]
  • [3] A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial
    Charbonnel, BH
    Matthews, DR
    Schernthaner, G
    Hanefeld, M
    Brunetti, P
    [J]. DIABETIC MEDICINE, 2005, 22 (04) : 399 - 405
  • [4] Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
    Colhoun, HM
    Betteridge, DJ
    Durrington, PN
    Hitman, GA
    Neil, HAW
    Livingstone, SJ
    Thomason, MJ
    Mackness, MI
    Charlton-Menys, V
    Fuller, JH
    [J]. LANCET, 2004, 364 (9435) : 685 - 696
  • [5] Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
    Dormandy, JA
    Charbonnel, B
    Eckland, DJA
    Erdmann, E
    Massi-Benedetti, M
    Kmoules, IK
    Skene, AM
    Tan, MH
    Lefébvre, PJ
    Murray, GD
    Standl, E
    Wilcox, RG
    Wlhelmsen, L
    Betteridge, J
    Birkeland, K
    Golay, A
    Heine, RJ
    Korányi, L
    Laakso, M
    Mokán, M
    Norkus, A
    Pirags, V
    Podar, T
    Scheen, A
    Scherbaum, W
    Schernthaner, G
    Schmitz, O
    Skrha, J
    Smith, U
    Taton, J
    [J]. LANCET, 2005, 366 (9493) : 1279 - 1289
  • [6] Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
    Duckworth, William
    Abraira, Carlos
    Moritz, Thomas
    Reda, Domenic
    Emanuele, Nicholas
    Reaven, Peter D.
    Zieve, Franklin J.
    Marks, Jennifer
    Davis, Stephen N.
    Hayward, Rodney
    Warren, Stuart R.
    Goldman, Steven
    McCarren, Madeline
    Vitek, Mary Ellen
    Henderson, William G.
    Huang, Grant D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (02) : 129 - U62
  • [7] Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
    Gaede, P
    Vedel, P
    Larsen, N
    Jensen, GVH
    Parving, H
    Pedersen, O
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (05) : 383 - 393
  • [8] Effect of a multifactorial intervention on mortality in type 2 diabetes
    Gaede, Peter
    Lund-Andersen, Henrik
    Parving, Hans-Henrik
    Pedersen, Oluf
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (06) : 580 - 591
  • [9] Gerstein HC, 2000, LANCET, V355, P253
  • [10] Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743